Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

4.540 -0.030 (-0.66%)

Delayed Quote Updated: 12:40 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 Next >

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript ↗

November 04, 2025

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

Via The Motley Fool

Topics Earnings

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Nuvation Bio Inc.

Via Business Wire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock ↗

November 03, 2025

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Via The Motley Fool

Topics Regulatory Compliance

Nuvation Bio to Participate in Upcoming Investor Conferences

October 30, 2025

From Nuvation Bio

Via Business Wire

4 Analysts Assess Nuvation Bio: What You Need To Know ↗

September 30, 2025

Via Benzinga

Analyst Expectations For Nuvation Bio's Future ↗

September 08, 2025

Via Benzinga

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

From Nuvation Bio

Via Business Wire

Why Nuvation Bio Stock Is Skyrocketing Today ↗

September 30, 2025

The bulls are lining up on Wall Street for this up-and-coming biotech stock.

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 07, 2025

From Nuvation Bio

Via Business Wire

Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗

September 05, 2025

Via Benzinga

Top 2 Health Care Stocks That May Plunge This Month ↗

September 05, 2025

Via Benzinga

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27, 2025

From Nuvation Bio

Via Business Wire

NUVB Sales Jump 1,043% on Drug Launch ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Nuvation Bio Inc (NYSE:NUVB) Reports Mixed Q2 2025 Results with Strong Revenue Beat but Cautious Market Reaction ↗

August 07, 2025

Nuvation Bio (NUVB) reported Q2 2025 results with a massive revenue beat ($4.83M vs. $364K est.) driven by IBTROZI launch, but EPS met expectations (-$0.17). Cash at $607.7M, pipeline progressing.

Via Chartmill

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 05, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

June 24, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval ↗

June 11, 2025

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

Via Benzinga

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

June 11, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 13, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

May 12, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Nuvation Bio Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.